Sorry, unable to follow Michael. Please try again.
I am a physician-scientist and board-certified medical oncologist with extensive experience leading oncology drug development from early-stage clinical translation through global, registrational Phase 3 programs. I currently serve as a Clinical Development Senior Medical Director at Pfizer, where I lead thoracic oncology clinical development strategy and execution for PF-08634404 (PF’4404)—a novel PD-1 x VEGF bispecific antibody—across multiple global Phase 3 NSCLC programs. My clinical leadership spans development strategy, protocol and trial design, trial execution, clinical data interpretation, regulatory briefing planning, and cross-functional governance. Previously, at AbbVie, I directed oncology early development programs across multiple solid tumors, leading clinical development and FDA regulatory strategy (including Breakthrough Therapy and Orphan Drug Designations) for telisotuzumab adizutecan (Temab-A / ABBV-400). Additionally, I drove clinical assessments and due diligence for high-impact external business development (ImmunoGen), M&A evaluations, and option agreements across ADCs, targeted therapies, and immuno-oncology. My expertise bridges clinical oncology, translational science, regulatory interactions, and asset strategy. I enjoy working at the intersection of scientific innovation and clinical execution to translate complex biological data into practical development strategies that bring novel therapies to cancer patients.